Watson Receives FDA Approval for Generic Percocet(R) 7.5mg/325mg and 10mg/325mg

- Will Represent Watson's 12th Generic Product Launch in 2003 -

Sep 08, 2003, 01:00 ET from Watson Pharmaceuticals, Inc.

    CORONA, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
 Inc. (NYSE:   WPI), a leading specialty pharmaceutical company, announced today
 that it has received final approval from the United States Food and Drug
 Administration on its Abbreviated New Drug Application for Oxycodone and
 Acetaminophen (APAP) tablets in 7.5mg/325mg and 10mg/325mg strengths.
 Oxycodone/APAP is the generic equivalent to Endo Pharmaceuticals' Percocet(R)
 tablets and is indicated for the relief of moderate to moderately severe pain.
 For the 12-months ending June 2003, Percocet(R) 7.5mg/325mg and 10mg/325mg had
 sales of approximately $142 million.
     (Logo:  http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
     The Company expects a full launch by late 2003 and timing is dependent on
 obtaining quota from the Drug Enforcement Administration, adequate supply of
 active ingredient, and build-up of launch quantities.
     About Watson Pharmaceuticals, Inc.
     Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading
 specialty pharmaceutical company that develops, manufactures, markets and
 distributes branded and generic pharmaceutical products.  Watson pursues a
 growth strategy combining internal product development, strategic alliances
 and collaborations and synergistic acquisitions of products and businesses.
     For press releases and other company information, visit Watson
 Pharmaceuticals' Web site at http://www.watsonpharm.com .
     Forward-Looking Statement
     Any statements contained in this press release that refer to future events
 or other non-historical facts are forward-looking statements that reflect
 Watson's current perspective of existing trends and information as of the date
 of this release.  Except as expressly required by law, Watson disclaims any
 intent or obligation to update these forward-looking statements.  Actual
 results may differ materially from Watson's current expectations depending
 upon a number of factors affecting Watson's business.  These factors include,
 among others, risks and uncertainties detailed in Watson's periodic public
 filings with the Securities and Exchange Commission, including but not limited
 to Watson's Annual Report on Form 10-K for the year ended December 31, 2002
 and its Quarterly Report on Form 10-Q for the quarters ended March 31 and June
 30, 2003.
     Percocet(R) is a registered trademark of Endo Pharmaceuticals, Inc.

SOURCE Watson Pharmaceuticals, Inc.